Dianthus Therapeutics, Inc. /DE/

Developing selective antibody therapies for severe autoimmune diseases.

DNTH | US

Overview

Corporate Details

ISIN(s):: US2528281080 (+1 more)
LEI:
Country:: United States of America
Address:: 7 TIMES SQUARE, 10036 NEW YORK
Website:: https://dianthustx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies for severe autoimmune diseases. The company focuses on designing and engineering potentially best-in-class monoclonal antibodies with improved potency, high selectivity, and extended half-lives. Its lead candidate, claseprubart (DNTH103), is an antibody that selectively targets the active C1s complement protein. The pipeline also includes DNTH212, a bifunctional inhibitor targeting Type 1 IFN suppression and B cell modulation. Dianthus's therapeutic approach aims to enable less frequent and more convenient self-administered subcutaneous injections, with the goal of improving clinical outcomes and quality of life for patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Dianthus Therapeutics, Inc. /DE/ filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Dianthus Therapeutics, Inc. /DE/

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Dianthus Therapeutics, Inc. /DE/ via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
KOMIPHARM INTERNATIONAL CO., LTD. Develops animal health products and novel drugs for human cancer and autoimmune diseases.	South Korea	041960
KOREA ARLICO PHARM CO.,LTD. Manufactures generic drugs and provides CDMO services to a global market.	South Korea	260660
KOREAN DRUG CO., LTD. Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.	South Korea	014570
Korro Bio, Inc. A clinical-stage biopharma using RNA editing to develop medicines for rare & prevalent diseases.	United States of America	KRRO
K Pharma,Inc. Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.	Japan	4896
Kringle Pharma,Inc. Develops regenerative HGF medicines for rare and intractable neurological diseases.	Japan	4884
Krka Develops and sells generic prescription, non-prescription, and animal health products globally.	Slovenia	KRKG
Krystal Biotech, Inc. Developing redosable gene therapies for rare diseases using a modified HSV-1 vector.	United States of America	KRYS
KUKJEON PHARMACEUTICAL Co.,Ltd A chemical solutions provider manufacturing Active Pharmaceutical Ingredients and electronic materials.	South Korea	307750
Kura Oncology, Inc. Develops targeted precision medicines for high-need cancers like leukemia, head & neck, and lung cancer.	United States of America	KURA